Kodu・Aktsiate loetelu・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Suletud

10.52 4.68

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.8

Max

10.36

Põhinäitajad
By Trading Economics
Sissetulek	-4.3M -18M
Aktsiakasum	-0.19
Töötajad	37
EBITDA	-5.3M -17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+183.38% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	3. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-221M 903M
Eelmine avamishind	5.84
Eelmine sulgemishind	10.52

Corvus Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. okt 2026, 23:56 UTC

Southwest Gas Holdings Inc's shares were roughly flat in after-market trading, showing limited movement since Thursday's close within a narrow range.

8. okt 2026, 23:56 UTC

Yum Brands Inc. is experiencing a decline in after-market trading, retracing to near the low end of its range following four consecutive higher daily closes.

8. okt 2026, 23:56 UTC

Correlated Moves

TE Connectivity PLC is trading modestly higher in after-market hours, supported by positive market sentiment following improved Medicare Advantage Star Ratings for Humana.

8. okt 2026, 23:56 UTC

Dropbox Inc shares are trading slightly higher in after-market hours, rebounding from an initial dip since Thursday's close.

8. okt 2026, 23:56 UTC

Fluor Corp's shares are trading lower in after-market hours, declining slightly since Thursday's close and remaining below its 20-day moving average.

8. okt 2026, 23:56 UTC

T Rowe Price Group Inc's shares traded roughly flat in after-market hours, reflecting stable conditions with slight fluctuations around Thursday's close.

8. okt 2026, 23:56 UTC

Correlated Moves

Southside Bancshares Inc's shares were little changed in after-market trading, remaining below their 20-day moving average amid broader subdued performance.

8. okt 2026, 23:56 UTC

Correlated Moves

Peoples Bancorp Inc is trading slightly higher in after-market hours, moving in sympathy with Nicolet Bankshares, Inc, which has also gained ground.

8. okt 2026, 23:56 UTC

Correlated Moves

United Bankshares Inc is little changed in after-market trading, moving in sympathy with Nicolet Bankshares, which has seen a slight increase since the previous close.

8. okt 2026, 23:56 UTC

Correlated Moves

Hancock Whitney Corp is slightly higher in after-market hours following Nicolet Bankshares, Inc.'s earnings release, despite its price remaining little changed overall.

8. okt 2026, 23:56 UTC

Stanley Black & Decker Inc shares are trading lower in after-market hours, retracing from earlier gains and nearing the lower end of their one-month trading range.

8. okt 2026, 23:56 UTC

Correlated Moves

Independent Bank Corp is little changed in after-market trading, moving in sympathy with Nicolet Bankshares, which has seen unusual activity.

8. okt 2026, 23:56 UTC

Wyndham Hotels & Resorts Inc saw a modest rise in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month range.

8. okt 2026, 23:56 UTC

Novanta Inc shares are trading slightly higher in after-market hours, maintaining a flat position since Thursday's close, despite recent lower finishes.

8. okt 2026, 23:56 UTC

Correlated Moves

NBT Bancorp Inc is trading higher in after-market hours, moving in sympathy with Nicolet Bankshares, which has also gained ground.

8. okt 2026, 23:55 UTC

New Jersey Resources Corp is trading higher in after-market hours, recovering from an early decline, though still below its 20-day moving average.

8. okt 2026, 23:55 UTC

Match Group Inc shares are trading modestly lower in after-market hours, continuing a trend seen in earlier sessions despite recent gains in the previous three trading days.

8. okt 2026, 23:55 UTC

Monster Beverage Corp shares are trading modestly higher in after-market hours, maintaining an upward trend since Thursday's close and staying above its 20-day moving average.

8. okt 2026, 23:55 UTC

Coastal Financial Corp is trading higher in after-market hours, recovering from earlier lows.

8. okt 2026, 23:55 UTC

Geo Group Inc shares have drifted lower during after-market trading, retracing from an early peak and settling in the middle of their one-month trading range.

8. okt 2026, 23:55 UTC

Wix.Com Ltd's shares traded roughly flat during after-market hours, showing a slight upward drift from earlier negative territory, remaining below its 20-day moving average.

8. okt 2026, 23:55 UTC

Motorola Solutions Inc. is trading higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

8. okt 2026, 23:55 UTC

Enpro Inc's shares are trading higher in after-market hours, gaining slightly since Thursday's close amid a broader market trend of four consecutive lower sessions.

8. okt 2026, 23:55 UTC

Azenta Inc shares are trading slightly higher in after-market hours, maintaining a position above the 20-day moving average following recent declines.

8. okt 2026, 23:55 UTC

Crocs Inc shares are modestly higher in after-market hours, settling around recent levels after a sharp rise earlier in the session.

8. okt 2026, 23:55 UTC

Advance Auto Parts Inc shares traded roughly flat during after-market hours, maintaining a narrow range since Thursday's close and positioned above its 20-day moving average.

8. okt 2026, 23:55 UTC

Constellation Energy Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

8. okt 2026, 23:55 UTC

NNN REIT Inc has advanced modestly in after-market trading, recovering from an initial dip to close at its highest level of the session.

8. okt 2026, 23:55 UTC

Pinnacle Financial Partners Inc is seeing a slight increase in after-market trading, gaining ground since Thursday's close while remaining near the lower end of its one-month range.

8. okt 2026, 23:55 UTC

Lindsay Corp's shares are modestly higher in after-market trading, recovering from earlier lows while approaching the session's highest point.

Võrdlus sarnastega

Hinnamuutus

Corvus Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

183.38% tõus

12 kuu keskmine prognoos

Keskmine 29.5 USD 183.38%

Kõrge 33 USD

Madal 27 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Corvus Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Corvus Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.